Please sign in to follow a disease.
Hairy cell leukemia variant
MONDO:0017600Hairy Cell Leukemia variant (HCL-V) is defined as a rare and indolent form of small, mature, B-cell leukemia characterized by splenomegaly, an elevated white blood cell (WBC) count and hyper-cellular bone marrow. HCL-V is more aggressive and resistant to therapy than classical HCL (HCL-C).
Also known as: HCL-V, HCL-v, hairy cell leukemia variant, leukemic reticuloendotheliosis variant, prolymphocytic variant of HCL, prolymphocytic variant of hairy cell leukaemia, prolymphocytic variant of hairy cell leukemia
2038 clinical trials for this condition and its sub-types, 9 tagged with Hairy cell leukemia variant itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
Can a second drug wipe out hidden leukemia cells?
Cure OngoingThis trial tests whether adding rituximab to the standard drug cladribine can eliminate leftover cancer cells in people with hairy cell leukemia, a rare blood cancer. Half the participants receive both drugs at the start, while the other half get rituximab later only if needed. T…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Cure
Last updated Aug 20, 2026 00:00 UTC
-
Targeted drug ibrutinib shows promise against rare leukemia
Disease control OngoingThis phase 2 trial tests the drug ibrutinib in 44 people with hairy cell leukemia that has come back after treatment. Ibrutinib works by blocking a protein that helps cancer cells grow. The main goal is to see how many patients achieve remission within 32 weeks.
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New hope for rare leukemia: targeted pill tackles relapse
Disease control OngoingThis study tests a pill called venetoclax for people whose hairy cell leukemia has returned after prior treatment. The drug blocks a protein that cancer cells need to survive. About 20 adults will take venetoclax to see if it shrinks tumors and improves blood counts, with the goa…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Can a Two-Drug combo beat back Tough-to-Treat hairy cell leukemia?
Disease control OngoingThis phase 2 trial is testing whether adding the antibody rituximab to either pentostatin or bendamustine can improve outcomes for people with hairy cell leukemia that has relapsed or not responded to standard treatments. Participants are randomly assigned to one of the two drug …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug duo aims to tackle rare leukemia
Disease control By invitation onlyThis phase 2 trial is testing a combination of two drugs, rituximab and zanubrutinib, in people with hairy cell leukemia or its variant. The goal is to see if this treatment can shrink or eliminate the cancer. Participants take zanubrutinib pills daily and receive rituximab infus…
Phase 2 • Sponsor: Bnai Zion Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New combo therapy targets rare blood cancer in early trial
Disease control OngoingThis early-phase study tests the safety of combining two drugs, moxetumomab pasudotox and rituximab, for people with hairy cell leukemia that has not responded to standard treatment. About 18 adults will receive up to 8 cycles of the drugs through an IV. The main goal is to find …
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC